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F-BAR domain only proteins 1 and 2 (FCHO1/FCHO2) are involved in the maturation of clathrin-coated pit formation. 2 Through the N-terminal F-BAR domain, they bind to phosphatidylinositol 4,5-biphosphate on the inner side of the cell membrane, inducing and stabilizing membrane curvature. 3 In addition, the FCHO1/FCHO2 C-terminal m-homology domain mediates interaction with the epidermal growth factor receptor substrate 15 and cargo molecules. 3 Moreover, the linker region of FCHO1 acts as an allosteric activator of the adaptor protein 2 complex, enabling recruitment of clathrin to the assembling coat. 4, 5 Here we report 5 patients (P1-P5) from unrelated families of Italian (P1), Turkish (P2, P3, and P5) and Algerian (P4) origin (Fig 1, A) with biallelic FCHO1 mutations and combined immunodeficiency, manifesting as recurrent and severe infections of bacterial, mycobacterial, viral, and fungal origin and profound T-cell lymphopenia (Table I and see Fig E1 and the Methods section in this article's Online Repository at www.jacionline. org). P3 had EBV-negative diffuse large B-cell lymphoma. Three patients (P3-P5) died in childhood, whereas P1 and P2 are alive with full donor chimerism after allogeneic hematopoietic stem cell transplantation (HSCT) and have cleared pretransplantation infections. Whole-exome sequencing (P1, P2, P4, and P5) and targeted sequencing of a large panel of primary immune deficiency-related genes (P3) identified biallelic private FCHO1 mutations, which were subsequently confirmed by means of Sanger sequencing (Fig 1, B , and see Fig E2,  Table E1 , and the Methods section in this article's Online Repository at www.jacionline.org).
Patients P2, P3, and P4 carried homozygous frameshift mutations predicted to cause premature termination. Western blotting analysis of HA-or FLAG-tagged FCHO1 constructs showed expression of truncated products corresponding to P2 and P3, whereas no protein was detected for P4 (Fig 1, C) .
P1 was homozygous for a splice-site mutation (c.120-1G>C) at the acceptor splice site of intron 5, which was predicted to result in exon 6 skipping. Because no pre-HSCT specimens were available, we performed RT-PCR analysis in PBMCs from her parents, who are both heterozygous for the mutation. Amplification with primers in exons 4 and 9 identified 2 bands in P1's parents; cloning and sequencing confirmed that the lower band corresponds to a product lacking exon 6 (Fig 1, D) . This abnormal splicing is predicted to cause an in-frame, internally truncated FCHO1 protein lacking amino acids 41 to 65 within the F-BAR domain (Fig 1, B) .
P5 was homozygous for the c.2711G>A mutation, which was predicted to disrupt the intron 2 donor splice site and the correct FCHO1 amino acid sequence after Trp9 (Fig 1, B) . No samples were available to test the consequences of this mutation at the cDNA level.
We performed quantitative PCR analysis of FCHO1 and FCHO2 expression in control CD4
1 and CD8 1 T cells, CD19
1 B cells, CD56 1 natural killer cells, fibroblasts, and the K562 erythroleukemic cell line and observed differential expression. FCHO1 was predominantly expressed in lymphoid cells, whereas FCHO2 was more abundantly expressed in fibroblasts and K562 cells (see Fig E3 in this article's Online Repository at www.jacionline.org).
To clarify the mechanisms underlying the T-cell lymphopenia observed in the patients, we first analyzed T-cell activation and proliferation in PBMCs from healthy control subjects and P2, the only patient from whom pre-HSCT PBMCs were available. T cells from P2 displayed normal expression of early and late T-cell activation markers (CD69, CD25, and CD71) but reduced proliferation on activation through CD3/CD28 (see Fig E4, A and B, in this article's Online Repository at www.jacionline.org). In particular, T cells from P2 entered only 2 to 4 rounds of cell division, whereas T cells from control subjects entered 5 to 7 rounds of proliferation. Because each round of division that fails to occur in the patient results in an exponential loss in T-cell numbers, 6 the reduced number of cell divisions observed in P2 represents a significant proliferation defect. Prior studies have demonstrated that clathrin-mediated endocytosis is important for mitosis. 7 We found that after activation through CD3/CD28, PBMCs from P2 showed a high percentage of hypodiploid cells, a marker of apoptosis, and reduced percentages of cells in the S and G2/M phases of the cell cycle (Fig 1, E) . Notably, no abnormalities of T-cell repertoire diversity, composition, and clonal abundance were observed in circulating T cells from P2 (see Fig E5 in this article's Online Repository at www.jacionline.org). Overall, these results strongly suggest that defective T-cell proliferation and increased activation-induced cell death, rather than impaired thymic output, are major contributors to the T-cell lymphopenia observed in patients with FCHO1 deficiency.
Finally, to investigate whether FCHO1 mutations affect CME, we analyzed transferrin internalization, which relies mainly on clathrin-dependent endocytosis. We previously demonstrated that a missense mutation in TFRC, which encodes the transferrin receptor (TfR), impairs transferrin internalization and intracellular iron delivery, causing a combined immunodeficiency with defective T-cell proliferation. 8 TfR expression on the surfaces of resting PBMCs is minimal but increases at 48 and 72 hours after T-cell receptor (TCR) activation. 8 Therefore we stimulated PBMCs from P2 and control subjects with anti-CD3 and Protein A for 48 and 72 hours. A chase experiment was then performed by adding biotinylated transferrin, followed by streptavidin-phycoerythrin (PE), to measure the amount of biotinylated transferrin remaining on the cell surface after 30 minutes. Although transferrin internalization was readily observed in control T cells, it was minimally detectable in P2's T cells (Fig 1, F) , which is consistent with previous observations that disruption of the FCHO1 and FCHO2 genes significantly FIG 1. A, Pedigrees of patients (P1-P5) with FCHO1 mutations. B, Schematic representation of FCHO1 protein and predicted effects of mutations on protein structure. Gray boxes represent spurious amino affects the rate of TfR internalization but does not completely abrogate it. 5 Along with the different degree of impairment of T-cell proliferation, these findings distinguish FCHO1 deficiency from TFRC deficiency. In contrast, TCR/CD3 internalization, which is clathrin independent, 9 was preserved in activated T cells from P2 (see Fig E4, C) .
In summary, we have demonstrated that FCHO1 deficiency is a novel form of combined immunodeficiency with impaired T-cell proliferation, increased activation-induced T-cell death, and defective CME. RT-PCR amplification of partial (exons 4-9) FCHO1 transcript in PBMCs from a healthy control subject and from P1's father and mother. Bottom, Schematic representation of effects at the transcript level, as predicted on cloning and sequencing of the 614-bp (top) and 539-bp (bottom) products, respectively. E, Left, Fluorescence-activated cell sorting (FACS)-based cell-cycle analysis on T-cell activation through CD3 and CD28 for 72 hours in P2 and 2 healthy control subjects. Staining with propidium iodide (PI) marks hypodiploid (hypod.) cells, as well as cells in the G0/G1, S, and G2/M phases of the cell cycle. Right, Proportion of PBMCs that were hypodiploid or in various phases of the cell cycle. F, Left, FACS analysis of the kinetics (t 5 0 and 30 minutes) of transferrin internalization in T cells from 2 healthy control subjects and P2 on stimulation with anti-CD3 plus Protein A for 48 hours (top) and 72 hours (bottom). Right, Graphic representation of biotinylated transferrin present on the cell surface at time point t 5 30 minutes relative to t 5 0 minutes. 
=

METHODS Patients
All study participants were recruited after obtaining informed consent, and the study was approved by the institutional review board of the referring institutions (National Institutes of Health protocols 06-I-0015 and 16-I-N139).
P1, of Italian origin, was born to first-cousin parents (Fig 1, A) and manifested recurrent respiratory and gastrointestinal tract infections since the first months of life. At the age of 3 years, she was admitted for Pneumocystis jirovecii pneumonia, diarrhea, and growth failure (weight, 12.9 kg, less than the third percentile; length, 97 cm, less than the third percentile). Laboratory examinations revealed profound lymphopenia (Table I ). An abdominal computed tomographic (CT) scan showed diffuse mesenteric lymphadenopathy, and a lymph node biopsy specimen grew Mycobacterium genavense. At the age of 3 years and 7 months, the patient received a matched unrelated donor hematopoietic cell transplantation with myeloablative conditioning. The clinical course after transplantation was complicated by chronic graftversus-host disease, autoimmune hemolytic anemia, and portal hypertension. She is currently alive at 17 years of age, with multilineage full donor chimerism. Her mycobacterial disease has resolved, but because of intestinal chronic graft-versus-host disease, she remains with low weight (35.9 kg) and height (128 cm).
P2, a boy born to consanguineous parents of Turkish origin (Fig 1, A) , had recurrent respiratory tract infections and growth failure (weight, 7.8 kg, les than the third percentile) since 6 months of age. Laboratory investigations revealed T-cell lymphopenia, decreased serum IgM levels, and poor antibody responses (Table I) . No thymic shadow was visible at chest radiography, and a chest CT scan demonstrated diffuse bronchiectasis (Fig E1, A) . He was initially treated with intravenous immunoglobulin and antimicrobial prophylaxis and received a matched unrelated donor hematopoietic cell transplantation with myeloablative conditioning at the age of 2.5 years. The posttransplantation course was complicated by engraftment syndrome, which was successfully treated with steroids, and grade II acute graft-versus-host disease. He is currently alive and well, with full donor chimerism at 4 years of age.
His older brother was admitted at 1 year of age with a history recurrent pneumonias, diarrhea, candidiasis, and growth failure (weight, 5 kg, less than the third percentile) since the age of 7 months. Laboratory tests revealed T-and B-cell lymphopenia, hypogammaglobulinemia, and impaired antibody responses, for which he was treated with intravenous immunoglobulin. At the age of 6 years, he had severe pneumonia, Candida species-related sepsis, and vesicular lesions on his back. Despite extensive antibacterial and antifungal therapy, he developed multiorgan failure and died. P3, a male child born to apparently nonconsanguineous parents from the same small village in Turkey, was admitted at the age of 8 years because of fever and dyspnea. Ultrasound studies revealed diffuse lymphadenopathy, and high levels of EBV viremia (178,000 copies/mL) were demonstrated. During follow-up, both lymphopenia and neutropenia were observed (Table I) ; a bone marrow biopsy specimen was consistent with hemophagocytic lymphohistiocytosis. Because of persistent lymphadenopathy, a lymph node biopsy was performed and revealed a diffuse EBV-negative large B-cell lymphoma. His clinical course was complicated by respiratory failure, leading to death. P4, a female child born to consanguineous parents of Algerian origin, had an older sister with a history of disseminated BCG, chronic diarrhea, and recurrent pneumonias who died from a severe pneumonia resulting in acute respiratory failure. P4 had recurrent pneumonias, chronic diarrhea, skin abscesses, and refractory dermatophytosis at 4 months of age. By 2.5 years of life, she experienced neuromotor regression, with an inability to stand or sit, ataxia, hypermetria, and tremors. Immunologic evaluation at 2.5 years of life was notable for CD4 1 and CD8 1 lymphopenia, reduced IgM and IgA levels, reduced B-cell numbers, and nearly absent memory B cells. She continued to have recurrent pneumonias and died at 4 years of age of respiratory failure. P5, a female child born to first-cousin parents of Turkish origin, was admitted at 6 years of age with fever, dyspnea, oral thrush, new-onset ataxia and seizures. She had no history of prior recurrent infections. Chest and abdominal CT revealed bilateral areas of consolidation and nodular opacities, as well as hepatic lesions that were identified as granulomas on histologic analysis. Cultures of bronchoalveolar lavage fluid were positive for Klebsiella pneumoniae. Brain magnetic resonance imaging revealed multiple 1.5-cm nodules in the right cerebellar hemisphere. Laboratory testing at that time was notable for CD4 1 T-cell lymphopenia, increased IgM levels, and EBV viremia (38,000 copies/mL). During this hospitalization, she had worsening respiratory failure accompanied by increasing size of cerebellar lesions despite treatment with meropenem, vancomycin, metronidazole, acyclovir, and amphotericin B. Histologic analysis of the brain lesions revealed angiocentric and angiodestructive lymphoid infiltrate admixed with histiocytes, with atypical CD20 1 lymphoid cells positive for EBV and CD30, which is consistent with a diagnosis of lymphomatoid granulomatosis. She was treated with rituximab and prednisone but died of respiratory failure.
Whole-exome sequencing, targeted sequencing, and Sanger DNA sequencing
For P1 and P2, genomic DNA samples were isolated from PBMCs by using the DNeasy Blood & Tissue Kit (69506; Qiagen, Hilden, Germany). After quality control, whole-exome sequencing (WES) for family 1 was performed with the VCRome 2.1 capture kit from NimbleGen and sequenced as paired-end 75-bp reads with the Illumina HiSeq 2500 Platform (Illumina, San Diego, Calif). For family 2, WES was performed with the Agilent Human V5 (51MB) Kit (Agilent Technologies, Wagh€ ausel-Wiesental, Germany) coupled with paired-end 125-bp reads by using HiSeq 2500. All DNA samples were sequenced so that more than 85% of the bases were covered at 203 or greater. All sequenced DNA reads were mapped to the hg19 human genome reference by using the Burrows-Wheeler Aligner with default parameters. Single nucleotide variant and indel calling were performed by using the Genome Analysis Toolkit (version 3.4; the Broad Institute, http://www.broadinstitute.org/gatk/).
Variants were then annotated by using VEP and filtered by using GEMINI E1 based on autosomal recessive mode of inheritance, a minor allele frequency of less than 0.01 in the ExAC browser, and the nonsynonymous nature of variants falling in coding regions or in splice sites. Blacklisted E2 nonpathogenic common variants were also filtered out. Variant conservation and functional prediction, gene expression pattern, and available known biological knowledge were used to prioritize the candidate variants to identify the disease causal variant from rare family private variants.
For P3, genomic DNA was enriched with the HaloPlex Target Enrichment System (Agilent Technologies), and targeted sequencing of 500 primary immune deficiency genes and data analysis were performed, as previously described.
E3
For patients P4 and P5, genomic DNA was isolated from whole blood by using the Gentera Puregene Cell Kit (Qiagen). Exome capture was performed by using the Agilent SureSelect V5, 51MB (Agilent Technologies). The Illumina HiSeq-2500 (Illumina) was used to perform paired-end sequencing, generating 100 base reads. The average coverage of the exome for P4 and P5 was 973 and 863, respectively. Sequence processing and mapping to the human reference genome assembly GRCh37 was performed with the Burrows-Wheeler Aligner, SAMtools, and Picard Tools. Variants were called by using the Genome Analysis Toolkit.
For all filtered variants, CADD PHRED scores, CADD_MSC, and pLi algorithms were used to assess the in silico predicted pathogenicity. FCHO1 mutations were verified by means of Sanger sequencing in family members, and primer pairs are shown in Table E2 .
Quantitative real-time PCR analysis
Normal donor PBMCs were stained and underwent fluorescence-activated cell sorting for surface expression of CD3 (eFluor450 mouse anti-human CD3, catalog #48003742, clone OKT3; Fisher Scientific, Waltham, Mass), CD4 (allophycocyanin [APC]-Cy7 mouse anti-human CD4 antibody, catalog #341095, clone SK3; BD Biosciences, San Jose, Calif), CD8 (PE mouse anti-human CD8 antibody, catalog #301008, clone RPA-T8; BioLegend, San Diego, Calif), CD19 (peridinin-chlorophyll-protein complex/Cy5.5 mouse anti-human CD19 antibody, catalog #302230, clone HIBI19; BioLegend), and CD56 (fluorescein isothiocyanate [FITC] mouse anti-human CD56 antibody, catalog #340723, clone NCAM16.2; BD Biosciences), respectively, by using FACSAria. Total RNAwas extracted from cells by using the RNeasy Micro Kit (Qiagen), according to the manufacturer's instructions. For each sample, cDNA was generated from RNA in a total volume of 20 mL by using the qScript cDNA Synthesis Kit (Quantabio, Beverly, Mass). Real-time PCR was performed with TaqMan Fast Advanced Master Mix (Applied Biosystems, Foster City, Calif) and TaqMan probes for human ACTB (Hs99999903_m1), FCHO1 (Hs00322606_m1), and FCHO2 (Hs01564786_m1; all from Thermo Fisher Scientific). Experiments were run on a 7500 Real Time PCR System (Applied Biosystems) with 7500 Real Time PCR software (version 2.3; Life Technologies, Grand Island, NY). Data were analyzed by using the 2 2DCt method after normalization to the ACTB gene as an endogenous control by using water as a negative control.
In vitro mutagenesis, transfection, and Western blotting
Targeted mutagenesis for mutations in P2 (c.2023dupG, p.V675Gfs*33) and P3 (c.1304_1305del, p.F436Wfs*7) was performed by using the Phusion Site-Directed Mutagenesis Kit (Thermo Fisher), according to the manufacturer's instructions. Wild-type (WT) cDNA of the human FCHO1 gene from a pDONR-223 vector (Arizona State University) was introduced in an N-terminal tagged pCMV-HA-N vector (Addgene, Watertown, Mass), and the mutagenic primers FCHO1.P2 and FCHO1.P3 (see sequence below), which were designed by using the Phusion Site-Directed Mutagenesis Kit (Thermo Fisher) instructions, were used. Successful mutagenesis was confirmed my means of plasmid DNA sequencing at Macrogen (Seoul, Korea). One day before transfection, 293T cells were seeded (at 500,000 cells per well in a 6-well plate) in complete 10 6 ) were lysed with RIPA-NTG buffer (30 mmol/L Tris-Cl, 150 mmol/L NaCl, 1% NP-40, 1% Triton X-100, 10% glycerol, and 13 protease inhibitor) with protease inhibitor cocktail (Halt Protease Inhibitor Single-Use Cocktail 1003; Thermo Scientific) for 30 minutes on ice. Lysates were denaturated by using Bolt LDS Sample Buffer 43 and Bolt Reducing Agent 103 (Life Technologies) at 708C for 15 minutes, loaded on 4-12% Bis-Tris Gel, and separated by using SDS-PAGE. Proteins were transferred to nitrocellulose membrane by using the iBlot 2 System (Invitrogen). Blots were probed overnight with 1:2000 dilutions of rat Anti-HA High Affinity mAb (11867423001; Roche, Mannheim, Germany), and 1:2000 dilution of rabbit anti-b-actin mAb (4967S; Cell Signaling, Danvers, Mass) as a loading control. Bands were revealed by using SuperSignal West Femto kit (Fisher Scientific).
For the mutation c.189dupC (P4), HEK293T cells were transfected with N-terminal FLAG-tagged FCHO1 WT (Genecopoeia, Rockville, Md) or FCHO1.P4 plasmid DNA. The latter was generated by using the QuikChange II XL Site-Directed Mutagenesis Kit (Agilent Technologies) with FCHO1.P4 primers (see sequence below). One day after transfection by using the TransIT-LT1 Transfection Reagent (Mirus Bio, Madison, Wis), cells were lysed in RIPA buffer (Millipore, Burlington, Mass), 50 mmol/L EDTA (Thermo Scientific), and protease inhibitors (Thermo Scientific). Electrophoresis of lysates was performed on 4-12% precast polyacrylamide gels (Invitrogen), followed by immunoblotting with the following antibodies as indicated in figure legends: anti-FLAG (F3165, Sigma-Aldrich, St Louis, Mo) and anti-b-actin (Sigma-Aldrich).
Primers for in vitro mutagenesis
FCHO1.P2 primer forward, CCACCACCACCTGGTCCTCAGCTTCCG; FCHO1.P2 primer reverse, GGTCCCGCTGAACACACGCACGATG; FCHO1.P3 primer forward, GTTCTTGGACACCTGCTCCTCTGACTGC; FCHO1.P3 primer reverse, CTTTGGGCCGCCCCTGGAGTCAGCCTTTG; FCHO1.P4 primer forward, CAGCAACGGGACCCCCCATGGGGAC; and FCHO1.P4 primer reverse GTCCCCATGGGGGGTCCCGTTGCTG.
Analysis of RNA splicing
RNA extracted from PBMCs derived from a healthy donor and from the father and mother of P1 was retrotranscribed with random primers and the ImProm-II Reverse Transcription System (Promega), according to the manufacturer's instructions. RT-PCR for FCHO1 transcript was performed by using primers (forward, 59TCTCCACAGAGACCATCAGG39; reverse, 59GATGCTGGACTCAGCCCTG39) with an annealing temperature of 648C.
In vitro T-cell activation and proliferation
For analysis of T-cell activation, PBMCs from P2 and 2 healthy control subjects were cultured in 200 mL of serum-supplemented RPMI (SH30027.01; GE Healthcare Life Sciences, Fairfield, Conn) in round-bottom 96-well plates with 1 mg/mL anti-CD3 (OKT3, catalog #14-0037-82; eBioscience, San Diego, Calif) and 1 mg/mL Protein A (catalog #P6031; Sigma-Aldrich) for 24 and 48 hours. Cells were collected at 24 and 48 hours, washed with serumsupplemented PBS, and stained with Live/Dead (L34959; Invitrogen) staining and fluorochrome-conjugated CD3-PE/Cy7 (317334; BioLegend), TCRab-FITC (555547; BD PharMingen), CD71-APC (17-0719-42; Invitrogen), CD69-BV510 (310936; BioLegend), and CD25-eFluor780 (47-0259-42; Invitrogen) for 15 minutes at 48C (dark). On washing with serumsupplemented PBS, expression of CD69, CD25, and CD71 by CD3 
In vitro cell-cycle analysis
Total PBMCs were stimulated with Dynabeads Human T-Activator CD3/CD28 (Thermo Fisher) for 3 days. Cells were washed with PBS, fixed in 66% EtOH for 3 hours at 48C, and then washed twice in PBS 2 times and stained with propidium iodide (50 mg/mL) for 30 minutes at 378C in the presence of RNase A (100 mg/mL), followed by analysis with flow cytometry.
TCR internalization
PBMCs from P2 and 1 healthy control subject were either left unstimulated or stimulated with 0.5 mg/mL anti-CD3 (OKT3, catalog #14-0037-82; eBioscience) plus 0.5 mg/mL anti-CD28 (catalog #302914; BioLegend) in 500 mL of serum-supplemented RPMI at 378C for 2, 15, and 30 minutes. At each time point, cells were collected, washed with serumsupplemented PBS, and stained with Live/Dead (L34959; Invitrogen) staining and fluorochrome-conjugated CD3-eFluor450 (48-0037-42; eBioscience) and eBioscience) for 15 minutes at 48C (dark). Cells were washed with serum-supplemented PBS, acquired, and analyzed by using flow cytometry (LSRFortessa; BD) and FlowJo software (version 10.5.2; TreeStar). #14-0037-82; eBioscience) and 1 mg/mL Protein A (catalog #P6031; SigmaAldrich) at 378C for 48 and 72 hours. At each time point, cells were collected and washed with PBS at 300 relative centrifugal force units for 5 minutes and resuspended in 250 mL of RPMI serum-free media with 25 mmol/L HEPES (H3375-100G; Sigma) and 0.5% of BSA (15260-037; Life Technologies). Cells were starved for 30 minutes at 378C, washed once with PBS, resuspended in serum-free RPMI with biotinylated transferrin (T23363; Invitrogen) and 0.5% BSA, and pulsed for 30 minutes at 48C. Medium were then changed to serum-supplemented RPMI, and temperature was shifted to 378C for 0, 10, and 30 minutes to stimulate biotinylated transferrin trafficking. Internalization was stopped by incubating cells on ice and washing with cold PBS, followed by staining and flow cytometry. For the different time point of transferrin internalization, the percentage of surface transferrin expression was calculated as follows: 
